Trial reportPLoS pathogens2020
Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis.
Trial report in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 61 citations in OpenAlex.
- Non-Lactobacillus-Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Postbiotic gel relieves clinical symptoms of bacterial vaginitis by regulating the vaginal microbiota.Frontiers in cellular and infection microbiology · 2023Trial
- Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.The Lancet. Microbe · 2022Trial
- Testing the regulatory framework in South Africa - a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis.BMC infectious diseases · 2020Trial
- Characterization of vaginal lactobacilli from South African women toward the development of a biotherapeutic to optimize the vaginal microbiome.Applied and environmental microbiology · 2026Article
- Selection and Characterization of Vaginal Lactobacilli from Healthy Algerian Women with Potential Probiotic Properties Against Urogenital Pathogens.Antibiotics (Basel, Switzerland) · 2026Article
- High Burden of Vaginal Infections and Multidrug Resistance With Promising Probiotic Candidates From Cervicovaginal Microbiota in North Region, Cameroon.Probiotics and antimicrobial proteins · 2026Article
- Alleviative Effect of Vaginal Lactobacilli with Probiotic Potential from Healthy Chinese Women on Bacterial Vaginosis Caused by Gardnerella vaginalis in Mice.Probiotics and antimicrobial proteins · 2026Article
- VIRGO2: an enhanced gene catalog of the vaginal microbiome provides insights into its functional and ecology complexity.Nature communications · 2025Article
- Vaginal microbiome and preterm birth: Composition, mechanisms and microbiota‑directed therapies (Review).International journal of molecular medicine · 2025Review
- The Therapeutic Potential of Lactobacillus crispatus for Chronic Endometritis: A Comprehensive Clinical Trial and Experimental Investigation.Probiotics and antimicrobial proteins · 2025Article
- Practical media formulations for rapid growth ofApplied and environmental microbiology · 2025Article
- Antimicrobial and Anticancer Activities ofNutrients · 2025Article
- Gut-derivediMeta · 2025Article
- Beyond MRS Broth: A soytone medium towards affordable culturing of South African vaginal Lactobacillaceae isolates.Journal of industrial microbiology & biotechnology · 2024Article
- Riboflavin for women's health and emerging microbiome strategies.NPJ biofilms and microbiomes · 2024Review
- Ecology meets reproductive medicine in HIV prevention: the case for geography-informed approaches for bacterial vaginosis in Africa.Frontiers in reproductive health · 2024Review
- Review
- Potential Role of Vaginal Microbiota in Ovarian Cancer Carcinogenesis, Progression and Treatment.Pharmaceutics · 2023Review
- Microbiota dynamics, metabolic and immune interactions in the cervicovaginal environment and their role in spontaneous preterm birth.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics continue to be the standard-of-care for bacterial vaginosis (BV), although recurrence rates are high. Vaginal probiotics may improve durability of BV treatment, although few probiotics for vaginal health contain Lactobacillus spp. that commonly colonize the lower female genital tract. Characteristics of vaginal Lactobacillus strains from South African women were evaluated for their probiotic potential in vitro compared to strains from commercial vaginal products, including growth at varying pHs, ability to lower pH, produce D-/L-lactate and H2O2, influence growth of BV-associated Gardnerella vaginalis and Prevotella bivia, adherence to cervical cells and susceptibility to antibiotics. Fifty-seven Lactobacillus strains were purified from cervico-vaginal fluid, including L. crispatus, L. jensenii, L. gasseri, L. mucosae, and L. vaginalis. L crispatus strains grew better at pHs below 4.5 and lowered pH more effectively than other strains. Production of D-/L-lactate and H2O2 varied between Lactobacillus species and strains. Lactobacillus strains generally inhibited P. bivia more uniformly than G. vaginalis isolates. All vaginal Lactobacillus isolates were resistant to metronidazole while susceptibility to clindamycin varied. Furthermore, vaginal Lactobacillus strains tended to be broadly susceptible to penicillin, amoxicillin, rifampicin and rifabutin. Whole-genome-sequencing of five of the best-performing vaginal Lactobacillus strains confirmed their likely safety, due to antimicrobial resistance elements being largely absent, while putative intact prophages were present in the genomes of two of the five strains. Overall, vaginal Lactobacillus strains largely performed better in these in vitro assays than probiotic strains currently used in probiotics for vaginal health. Including the best-performing vaginal Lactobacillus isolates in a region-specific probiotic for vaginal health may result in improved BV treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.